Asthma News: Breaking Asthma News, Comments and Articles. - Page: 5

05:10 EST 1st February 2015 | BioPortfolio

Asthma News - Page: 5Twitter RSS

Read the latest Asthma News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Asthma.

Search or Follow Our Asthma - Page: 5 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Asthma - Page: 5 News.
You can also follow our Asthma - Page: 5 news stories on Twitter: @asthma_bio

Showing "asthma" News Articles 101 to 125 of 1,100+

Monday 12th January 2015

Concentra Urges Steps to Protect Against Flu-related Illness

With the latest update from the Centers for Disease Control and Prevention (CDC) showing influenza near epidemic proportions in 43 states, Concentra, a subsidiary of Humana Inc. (NYSE: HUM), is urging those at medical risk of complications to take steps to

Friday 9th January 2015

Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that its partner Retrophin, Inc. (NASDAQ:RTRX) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for Sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS). “Sparsentan has the potential to be a significant medicine, and coul...

Health Tip: Triggering Asthma Attacks

-- An asthma attack can be triggered by a host of factors, from things to which you're allergic to panic or fear. The American Lung Association says asthma can be brought on by: Respiratory infections such as the flu or common cold. Foods to...

Diagnosis of Allergic Bronchopulmonary Aspergillosis

Allergic bronchopulmonary aspergillosis occurs in patients with bronchial asthma or cystic fibrosis. This case series explores its clinical presentation and diagnostic challenges. Future Microbiology

MEXICHEM ACQUIRES THE DISTRIBUTION AND SALE LICENSE FOR HFC-227ea/P MEDICAL PROPELLANT FROM DUPONT FLUOROCHEMICALS

Product to be sold under market leading ZEPHEX® brand Tlalnepantla, State of Mexico, January 8, 2015 - Mexichem, S.A.B. de C.V. (BMV: MEXCHEM*) (“the Company” or “Mexichem”) announces that on December 31, 2014, its Mexichem Limited UK Ltd subsidiary, a division of Mexichem’s Fluor Chain, acquired from E.I. Du Pont de Nemours and Company the d...

Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015

TARRYTOWN, N.Y., Jan. 9, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2014 financial and operating results on Tuesday, February 10, 2015, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Ca...

Rapid weight gain in first three months of life increases asthma risk

Babies who gain weight rapidly in the first three months of life are more likely to develop asthma and for it to persist into adolescence. This is according to the latest research from the University of Bristol's Children of the 90s study, which anal...

Thursday 8th January 2015

Infinity Pharma to halt developing rheumatoid-arthritis treatment

Infinity Pharmaceuticals (NASDAQ:INFI) fell to the lowest in more than six weeks after the drug developer said it would halt testing of its lead drug as a treatment for rheumatoid arthritis. Shares dropped to $14.48, the lowest intraday price since N...

Generic prescribing is not appropriate for inhaled drugs

The UK is experiencing an explosion of new drugs and inhaler devices being licensed for people with respiratory disease, increasing the complexity of prescribing for people with asthma or chronic obstructive pulmonary disease (COPD). The management of how these new products are introduced into clinical practice is important because they may vary in type of inhaler device and licensing.

Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Jan. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present updated product development plans and a financial update at the upcoming 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15th at 9:00 a.m. PT (see webcast details ...

Colorado State University researchers combat respiratory illness in dairy workers

CSU’s (Fort Collins) High Plains Intermountain Center for Agricultural Health and Safety is examining the reasons that dairy workers are susceptible to asthma, chronic bronchitis and decreased lung function — and what can be done to decr...

Wednesday 7th January 2015

Nearly Half of Older Adults With Asthma, COPD Still Smoke: CDC

WEDNESDAY, Jan. 7, 2015 -- Close to half of U.S. adults over 40 who have trouble breathing due to asthma or COPD still continue to smoke, federal health officials reported Wednesday. The findings highlight the difficulty facing many smokers trying...

Janssen and Vectura partner for anti-inflammatory therapies for asthma/COPD

Vectura has entered into a global development and licence agreement with Janssen Biotech for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD. The collaboration will focus initially on the development of a Phase II candidate and has the potential to include additional clinical-stage candidates. Searching for more deal information? Current Partnering ...

The Multiple Myeloma Research Foundation and GNS Healthcare Announce Collaboration to Identify Potential New Multiple Myeloma Therapies

Initiative will deploy predictive big data analytics to analyze patient data from landmark CoMMpass Study™ to speed drug discovery and development for patients with multiple myeloma GNS Healthcare (GNS), a leading provider of analytics solutions for driving personalized interventions that improve population health, and the

Big Data: Big headache for the industry?

Précis:  Big Data, big opportunities. But if data sets aren’t linked, the possibilities become limited. The McKinsey Global Institute estimates that applying Big Data strategies...

Tuesday 6th January 2015

Vectura in Deal with Janssen on Asthma/COPD Drug

Vectura has entered into a global development and licence agreement with Janssen Biotech for the exclusive development of novel anti-inflammatory therapies for the treatment of asthma/COPD.

Janssen to use Vectura's inhaler tech for COPD, asthma

Vectura Group plc (LSE:VEC) granted the Janssen Biotech Inc. unit of Johnson & Johnson (NYSE:JNJ) an exclusive, worldwide license to use its dry power inhaler technology to develop anti-inflammatory therapies for asthma and chronic obstructive pulmon...

KaloBios drops CF progam after Phase II miss

KaloBios Pharmaceuticals Inc. (NASDAQ:KBIO) said it would discontinue development of KB001-A in cystic fibrosis after the compound failed a Phase II study in CF patients with Pseudomonas aeruginosa lung infections. The compound missed the primary end...

About 1 in 7 older adults has some form of lung disease: CDC

(HealthDay)—Nearly 15 percent, or about one out of seven, middle-aged and older U.S. adults suffer from lung disorders such as asthma or chronic obstructive pulmonary disease (COPD), health officials said Tuesday.

"Mickey and the Plow Horse," New Book From Psychologist Dr. Edward Dreyfus, Encourages Young Readers to Embrace Life of Creativity and Purpose

SANTA MONICA, Calif., Jan. 6, 2015 /PRNewswire/ -- Dr. Edward Dreyfus's first children's book draws upon his five decades of experience as a psychologist helping people discover their full potential. "Mickey and the Plow Horse" puts readers in the shoes of 12-year-old Mickey Branfield, a shy and lonely boy with asthma who is more comfortable with technology than with people – until an u...

Vectura and J&J shake on asthma/COPD deal

British firm Vectura has entered an agreement with Johnson & Johnson’s pharma unit Janssen to develop therapies for asthma and COPD. The collaboration will focus initially on the advance of a Phase II candidate and has the potential to include additional clinical-stage candidates. “Vectura’s role in this agreement is to apply its expertise in the development of products for airway-relate...

Lupin Launches Generic DIOVAN® Tablets

MUMBAI and BALTIMORE, January 6, 2015 /PRNewswire/ -- Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched its Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg, the generic for Novartis Pharmaceuticals Corporation's (Novartis) Diovan® Tablets 40 mg, 80 mg, 160 mg and 320 mg strengths, having received final appro...

Hypoxia Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com

ReportsnReports.com adds “Hypoxia – Pipeline Review, H2 2014” to its store. The report provides an overview of the Hypoxia – Pipeline Review, H2 2014. Dallas,Texas (PRWEB) January 06, 2015 The report "Hypoxia - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hypoxia. Hypoxia is a medical disorder which results when the body does no...

J&J and Vectura sign asthma/COPD deal

J&J and Vectura sign asthma/COPD deal

Britain's Vectura collaborates with Janssen in asthma, COPD

LONDON, Jan 6 (Reuters) - Vectura Group, a respiratory drugs specialist, will work with Janssen Biotech to develop treatments for asthma and lung disease COPD, it said on Tuesday.


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks